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In this issue of the Journal, the study by Etheridge et al. (1)
reports results of a clinical trial of raising the serum
potassium concentration as a novel approach to QT interval
shortening in patients with congenital long QT syndrome
(LQTS). The investigators studied patients with Human
Ether-a-go-go-Related Gene (HERG or KNCH2) potassium
channel mutations, which is the most commonly affected
gene in LQTS. These investigators found that raising the
serum potassium concentration an average of 1.2 mEq/l
caused nearly a 100-ms decrease in the QTc interval and
reduced QT dispersion. The QT interval shortening oc-
curred in each of eight patients with six different HERG
mutations. This was achieved by having patients take
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remarkable amounts of oral spironolactone and potassium.
For the four-week duration of the trial, the therapy ap-
peared to work and was well tolerated by the patients. The
trial did not address long-term tolerability or potential side
effects: it lacked a control group, and it was not powered to
test for arrhythmia or mortality reduction. Furthermore, the
investigators did not address how much shortening of the
QT interval and QT dispersion might be desirable. The
current report serves as an initial study for a longer-term
trial.
The use of potassium to suppress cardiac arrhythmias and
its effect on the QT interval is not new. Indeed, beginning
nearly 100 years ago it was recognized that potassium
supplementation could have arrhythmia-suppressing prop-
erties (2,3), and nearly 50 years ago it was shown directly to
shorten underlying cardiac action potentials (4). The prin-
cipal use of potassium was in correcting hypokalemia, yet it
was recognized that increasing the potassium concentration
within the normal range, or even above normal, occasionally
diminished arrhythmias and could even treat experimental
ventricular fibrillation successfully (5). In congestive heart
failure (CHF), aldosterone causes myocardial and vascular
fibrosis, direct vascular damage, baroreceptor dysfunction,
and inhibition of uptake of norepinephrine by myocardium;
blockade of these effects reduces morbidity and mortality in
patients with class III and IV heart failure. The RALES
trial studied 1,663 patients with an ejection fraction 35%
who were randomized to receive spironolactone versus
placebo. Almost all were taking angiotensin-converting
enzyme inhibitors, loop diuretics, and digoxin, but only 10%
of the patients were on a beta-blocker. In patients receiving
spironolactone, there was a reduction in blood pressure, a
lower incidence of hypokalemia, and an overall reduction of
mortality by 30%. A large proportion of the deaths were
sudden, and potentially an increase in serum potassium may
have played a large role in reducing the incidence of
malignant ventricular arrhythmias (6). Other clinical trials
in CHF have shown that amiloride, also a potassium-
sparing diuretic, raises serum potassium, shortens the QT
interval, and reduces ventricular ectopy (7).
The treatment of LQTS patients by increasing the serum
potassium concentration is founded in modern molecular
electrophysiology. Originating from the identification of
human analogues of a drosophilia (fruit fly) ion-channel
gene (HERG) (8), HERG was shown to encode an ion
channel with properties similar to the native rapidly acti-
vating delayed rectifier potassium channel (IKr) found in the
human heart (9,10). One observation was its “paradoxical”
response to increased extracellular potassium. In several
laboratories it was shown that increasing extracellular po-
tassium, which decreases the driving force for potassium ion
movement across heart and other cell membranes, in fact
caused the IKr amplitude to “paradoxically” increase, which
will shorten action potentials.
Potassium as a chronic therapy for LQTS has obvious
potential risks. It has a relatively narrow therapeutic margin
of safety, and as long-term therapy it will require careful
patient follow-up. Not every patient will easily tolerate the
daily intake of large doses of potassium. Spironolactone has
long-term side effects that potentially may limit its utility.
Indeed, 10% of patients in the RALES trial developed
gynecomastia. Nonetheless, this promising approach has the
potential advantage of spanning the different gene defects
involved in LQTS. It requires that HERG channels be
intact and responsive to increased extracellular potassium.
As the molecular mechanisms causing congenital LQTS
are understood, other novel clinical therapies may emerge
into clinical practice. In patients with sodium channel
mutations (LQT3, causing a persistent late inward current),
sodium channel-blocking drugs such as flecainide cause QT
interval shortening (11). This approach is limited to selected
LQT3 patients. In contrast, in Brugada syndrome patients,
where sodium current is reduced, flecainide therapy poten-
tially may worsen the disease. The drug nicorandil, an
adenosine triphosphate-sensitive potassium channel opener,
has been shown to decrease slightly the QT interval in
patients with LQTS, although it prolonged refractoriness
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(12). In LQT2 (HERG) channel mutations the “pharma-
cological rescue” of functional channels has been shown
experimentally by the therapeutically available drug fexofe-
nadine (13). This approach may offer a potentially well-
tolerated treatment, but it will likely be gene-specific
(HERG) and mutation-specific (protein trafficking-
defective mutations). A novel benzodiazepine drug, L3, has
been described that selectively increases the slowly activat-
ing delayed rectifier potassium current (IKs, defective in
LQT1) to shorten action potentials and suppress triggered
activity (14). As with the combination of potassium and
spironolactone, L3 has the potential of spanning the differ-
ent gene defects involved in LQTS; however, it is a new
compound whose clinical development is uncertain. Finally,
overexpression of HERG channels has been shown experi-
mentally to shorten ventricular action potentials and sup-
press triggered activity (but also prolongs refractoriness) in a
model of acquired LQTS (15). The clinical development of
potentially exciting new and novel therapies is hampered,
however, by our incomplete understanding of the complex
polygenetic and molecular mechanisms of LQTS, and by
diminished interest within the pharmaceutical industry for
relatively rare congenital ion-channel diseases.
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